IOVA Iovance Biotherapeutics, Inc. - Common Stock
$3,60
Precio · May 20, 2026
Fundamentales a fecha de May 7, 2026
Rango 52S
$2–$6
49% of range
Calificación del Analista
BUY
17 analysts
Precio Objetivo
$9
+145% upside
P/E (TTM)
-2.5
ROE
-56.0%
Margen de Beneficio Neto
-148.4%
IOVA Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
Precio
$3.60
Capitalización Bursátil
$1.12B
P/E (TTM)
-2.5
BPA (TTM)
$-1.09
Ingresos (TTM)
$264M
Rendimiento div.
—
ROE
-56.0%
Deuda/Capital
0.0
Rango 52S
$2 – $6
IOVA Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
Configure
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Ingresos y Beneficio Neto
$264M
2016-12-31
→
2025-12-31
BPA
$-1.09
2019-12-31
→
2025-12-31
Flujo de caja libre
$-336M
2016-12-31
→
2025-12-31
Márgenes
-148.4%
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
Métrica
Tendencia a 5 años
IOVA
Mediana de Pares
P/E (TTM)
-2.5
—
P/S (TTM) (P/V (TTM))
4.3
45.5
P/B (P/C)
1.6
4.8
EV / EBITDA
-2.1
—
Price / FCF (Precio / FCF)
-3.3
—
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
Métrica
Tendencia a 5 años
IOVA
Mediana de Pares
Operating Margin (Margen Operativo)
-153.1%
—
Net Profit Margin (Margen de Beneficio Neto)
-148.4%
-237.1%
ROA
-42.9%
-41.6%
ROE
-56.0%
-55.3%
ROIC
-57.4%
—
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
Métrica
Tendencia a 5 años
IOVA
Mediana de Pares
Debt / Equity (Deuda / Patrimonio)
0.0
1.0
Current Ratio (Ratio corriente)
3.2
5.7
Quick Ratio (Ratio Rápido)
2.7
—
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
Métrica
Tendencia a 5 años
IOVA
Mediana de Pares
Revenue YoY (Ingresos interanuales)
60.6%
—
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
Métrica
Tendencia a 5 años
IOVA
Mediana de Pares
IOVA Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
COMPRA
17 analistas
- Compra fuerte 3 17,6%
- Compra 10 58,8%
- Mantener 4 23,5%
- Venta 0 0,0%
- Venta fuerte 0 0,0%
Precio objetivo a 12 meses
10 analistas · 2026-05-20
Mediana
$9.50
← Por Debajo de Todos los Objetivos
$3.60
Mín
$4.00
Máx
$14.00
Objetivo mediano
$9.50
+164,3%
Objetivo medio
$8.80
+144,8%
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
Sorpresa Media
-0.04%
| Período | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|
| 31 de marzo de 2026 | $-0.19 | $-0.15 | -0.04% |
| 31 de diciembre de 2025 | $-0.18 | $-0.18 | -0.00% |
| 30 de septiembre de 2025 | $-0.25 | $-0.26 | 0.01% |
| 30 de junio de 2025 | $-0.33 | $-0.29 | -0.04% |
| 31 de marzo de 2025 | $-0.36 | $-0.24 | -0.12% |
Comparación con pares Métricas clave frente a competidores del sector
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| IOVA | $1.12B | -2.5 | 60.6% | -148.4% | -56.0% | — |
| GENB | — | — | — | — | — | — |
| CAPR | $1.66B | -12.8 | -11.6% | — | -51.1% | — |
| PVLA | $1.30B | -28.2 | 65.3% | -1610.6% | -110.1% | — |
| SLS | $577M | -15.1 | — | — | -55.4% | — |
| TSHA | $1.57B | -16.2 | 17.3% | -1115.3% | -44.0% | — |
| GLUE | $1.03B | — | 63.5% | -31.2% | -15.4% | — |
| INBX | $1.15B | -8.7 | 550.0% | -10773.5% | -365.9% | — |
| ARDX | $1.42B | -22.4 | 22.1% | -15.1% | -40.2% | — |
| RXRX | $2.16B | -2.8 | 26.9% | -863.4% | -62.9% | — |
| NVAX | $1.09B | 2.6 | 64.7% | 39.2% | -977.1% | — |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados 17
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $264M | $164M | $1M | · | · | · | · | $0 | $0 | $0 | $0 | $0 | |
| Cost of Revenue | $173M | $93M | $1M | · | · | · | · | · | · | · | · | · | |
| R&D Expense | $300M | $276M | $333M | $295M | $259M | $202M | $166M | $100M | $72M | $27M | $15M | $4M | |
| SG&A Expense | $152M | $152M | $106M | $104M | $84M | $60M | $41M | $28M | $21M | $27M | $12M | $8M | |
| Operating Expenses | $667M | $559M | $462M | $399M | $343M | $262M | $207M | $128M | $93M | $54M | $28M | $12M | |
| Operating Income | $-403M | $-395M | $-461M | $-399M | $-343M | $-262M | $-207M | $-128M | $-93M | $-54M | $-28M | $-12M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | · | · | $-5.7K | |
| Interest Income | $10M | $20M | $13M | $3M | $451.0K | $2M | $9M | $5M | $813.0K | $745.0K | $200.0K | $6.0K | |
| Other Non-op | · | · | · | · | · | · | · | · | · | · | $200.0K | $6.0K | |
| Pretax Income | $-393M | $-375M | $-448M | $-396M | $-342M | · | · | · | · | · | · | · | |
| Income Tax | $-2M | $-3M | $-3M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-391M | $-372M | $-444M | $-396M | $-342M | $-260M | $-198M | $-124M | $-92M | $-53M | $-28M | $-12M | |
| EPS (Basic) | $-1.09 | $-1.28 | $-1.89 | $-2.49 | $-2.23 | $-1.88 | $-1.59 | · | · | · | · | · | |
| EPS (Diluted) | $-1.09 | $-1.28 | $-1.89 | $-2.49 | $-2.23 | $-1.88 | $-1.59 | · | · | · | · | · | |
| Shares (Basic) | 357,345 | 289,877 | 235,131 | 159,259 | 153,406 | 138,301 | 124,336 | · | · | · | · | · | |
| Shares (Diluted) | 357,345 | 289,877 | 235,131 | 159,259 | 153,406 | 138,301 | 124,336 | · | · | · | · | · | |
| EBITDA | $-390M | $-383M | $-449M | $-390M | $-340M | $-261M | $-206M | $-128M | $-93M | $-54M | $-28M | · |
Balance general 28
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $163M | $116M | $115M | $232M | $78M | $67M | $14M | $82M | $145M | $107M | $34M | $45M | |
| Short-term Investments | $134M | $208M | $165M | $240M | $426M | $562M | $293M | $386M | $0 | $60M | $70M | $0 | |
| Receivables | $82M | $69M | $151.0K | · | · | · | · | · | · | · | · | · | |
| Inventory | $52M | $52M | $10M | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $12M | $12M | $17M | $7M | $4M | $7M | $9M | $7M | $4M | $3M | $277.0K | $66.0K | |
| Current Assets | $443M | $457M | $308M | $479M | $508M | $636M | $316M | $475M | $149M | $170M | $104M | $45M | |
| PP&E (Net) | $131M | $109M | $114M | $105M | $101M | $59M | $9M | $3M | $2M | $2M | $2M | $2M | |
| PP&E (Gross) | $180M | $145M | $142M | $122M | $110M | $65M | $13M | $7M | $5M | $4M | $3M | $2M | |
| Accum. Depreciation | $49M | $36M | $28M | $17M | $9M | $6M | $4M | $4M | $3M | $2M | $1M | $104.0K | |
| Intangibles | $279M | $282M | $229M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $8M | $369.0K | $270.0K | $189.0K | $2M | $13M | $3M | $3M | $4M | $0 | · | · | |
| Total Assets | $913M | $910M | $780M | $664M | $777M | $768M | $345M | $481M | $155M | $172M | $106M | $47M | |
| Accounts Payable | $22M | $28M | $33M | $27M | $27M | $14M | $16M | $3M | $1M | $863.0K | $958.0K | $1M | |
| Accrued Liabilities | $111M | $82M | $69M | $52M | $57M | $35M | $16M | $12M | $8M | $4M | $672.0K | $328.0K | |
| Short-term Debt | $1M | · | · | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $138M | $122M | $110M | $91M | $89M | $55M | $39M | $14M | $10M | $5M | $2M | $2M | |
| Capital Leases | $44M | $44M | $67M | $72M | $65M | $45M | $4M | $0 | · | · | · | · | |
| Deferred Tax | $32M | $32M | $17M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | · | $12M | $2M | $230.0K | · | · | · | · | |
| Total Liabilities | $215M | $200M | $196M | $164M | $156M | $112M | $46M | $15M | $10M | · | · | · | |
| Total Debt | $1M | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $17.0K | $13.0K | $11.0K | $8.0K | $7.0K | $6.0K | $5.0K | $5.0K | $3.0K | $3.0K | $2.0K | $2.0K | |
| Paid-in Capital | $3.46B | $3.10B | $2.59B | $2.07B | $1.79B | $1.49B | $869M | $839M | $395M | $324M | $208M | $121M | |
| Retained Earnings | $-2.78B | $-2.38B | $-2.01B | $-1.57B | $-1.17B | $-830M | $-571M | $-373M | $-249M | $-157M | $-104M | $-77M | |
| AOCI | $16M | $-1M | $3M | $-902.0K | $-601.0K | $19.0K | $220.0K | $-42.0K | $0 | $29.0K | $48.0K | $0 | |
| Stockholders' Equity | $699M | $710M | $585M | $500M | $622M | $656M | $299M | $466M | $145M | $167M | $104M | $45M | |
| Liabilities + Equity | $913M | $910M | $780M | $664M | $777M | $768M | $345M | $481M | $155M | $172M | $106M | $47M | |
| Shares Outstanding | 411,938,061 | 305,252,194 | 256,135,715 | 187,812,072 | 157,004,742 | 147,874,917 | 126,411,808 | 123,415,576 | 73,164,914 | 62,248,074 | 48,547,720 | 33,750,188 |
Flujo de Efectivo 17
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $13M | $11M | $12M | $9M | $3M | $1M | $1M | $956.0K | $952.0K | $978.0K | $999.0K | $88.0K | |
| Stock-based Comp | $62M | $110M | $63M | $84M | $70M | $41M | $24M | $20M | $12M | $19M | $9M | $4M | |
| Deferred Tax | $-2M | $-3M | $-3M | · | · | · | · | · | · | · | · | · | |
| Amort. of Intangibles | $23M | $26M | $10M | $0 | · | · | · | · | · | · | · | · | |
| Restructuring | $5M | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | $16M | $-100M | $12M | $10M | $41M | $12M | $13M | · | · | · | · | · | |
| Operating Cash Flow | $-302M | $-353M | $-362M | $-293M | $-228M | $-205M | $-159M | $-101M | $-79M | $-33M | $-18M | $-9M | |
| CapEx | $34M | $11M | $22M | $20M | $38M | $47M | $7M | $1M | $1M | $2M | $1M | $2M | |
| Investing Cash Flow | $47M | $-96M | $-155M | $256M | $132.0K | $-318M | $90M | $-386M | $59M | $9M | $-71M | · | |
| Debt Issued | · | · | · | · | $1M | · | · | · | · | · | · | · | |
| Net Debt Issued | · | · | · | · | $1M | · | · | · | · | · | · | · | |
| Stock Issued | $306M | $397M | $463M | $190M | $203M | $567M | · | $399M | $54M | $96M | $68M | $32M | |
| Net Stock Activity | $306M | $397M | $463M | $190M | $203M | $567M | · | $399M | $54M | $96M | $68M | · | |
| Financing Cash Flow | $301M | $391M | $463M | $190M | $239M | $576M | $6M | $424M | $59M | $97M | $78M | · | |
| Net Change in Cash | $47M | $-59M | $-57M | $154M | $11M | · | · | $-63M | $39M | $73M | $-11M | $25M | |
| Taxes Paid | $0 | $0 | $0 | · | · | · | · | $0 | $0 | $0 | $0 | $0 | |
| Free Cash Flow | $-336M | $-364M | $-384M | $-313M | $-266M | $-252M | $-166M | $-102M | $-80M | $-34M | $-20M | · |
Rentabilidad 7
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -153.1% | -240.9% | -38735.0% | · | · | · | · | · | · | · | · | · | |
| Net Margin | -148.4% | -226.8% | -37345.4% | · | · | · | · | · | · | · | · | · | |
| Pretax Margin | -149.2% | -228.6% | -37638.0% | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | -148.2% | -233.6% | -37762.1% | · | · | · | · | · | · | · | · | · | |
| ROA | -42.9% | -44.0% | -61.5% | -54.9% | -44.3% | -46.6% | -47.9% | -38.9% | -56.3% | -38.1% | -36.4% | · | |
| ROE | -56.0% | -50.2% | -70.6% | -88.6% | -51.9% | -37.9% | -60.4% | -34.3% | -58.9% | -39.0% | -37.2% | · | |
| ROIC | -57.4% | -55.2% | -78.2% | · | · | · | · | · | · | · | · | · |
Liquidez y Solvencia 3
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.2 | 3.7 | 2.8 | 5.2 | 5.7 | 11.6 | 8.1 | 33.0 | 15.1 | 34.1 | 63.8 | · | |
| Quick Ratio | 2.7 | 3.2 | 2.5 | 5.2 | 5.7 | 11.5 | 7.9 | 32.5 | 14.7 | 33.5 | 51.4 | · | |
| Debt / Equity | 0.0 | · | · | · | · | · | · | · | · | · | · | · |
Eficiencia 3
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.2 | 0.0 | · | · | · | · | 0.0 | 0.0 | 0.0 | 0.0 | · | |
| Inventory Turnover | 3.4 | 4.0 | 2.1 | · | · | · | · | · | · | · | · | · | |
| Receivables Turnover | 3.5 | 4.7 | 15.7 | · | · | · | · | · | · | · | · | · |
Tasas de Crecimiento 1
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 60.6% | 13699.0% | · | · | · | · | · | · | · | · | · | · |
Valoración (TTM) 14
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $264M | $164M | $1M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income TTM | $-391M | $-372M | $-444M | $-396M | $-342M | $-260M | $-198M | $-124M | $-92M | $-53M | $-28M | $-12M | |
| Market Cap | $1.12B | $2.26B | $2.08B | $1.20B | $3.00B | $6.81B | $3.50B | $1.09B | $585M | $433M | $375M | · | |
| Enterprise Value | $829M | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | -2.5 | -5.8 | -4.3 | -2.6 | -8.6 | -24.7 | -17.4 | · | · | · | · | · | |
| P/S | 4.3 | 13.8 | 1751.4 | · | · | · | · | · | · | · | · | · | |
| P/B | 1.6 | 3.2 | 3.6 | 2.4 | 4.8 | 10.4 | 11.7 | 2.3 | 4.0 | 2.6 | 3.6 | · | |
| P / Tangible Book | 2.7 | 5.3 | 5.9 | 2.4 | 4.8 | 10.4 | · | · | · | · | · | · | |
| P / Cash Flow | -3.7 | -6.4 | -5.8 | -4.1 | -13.1 | -33.2 | -22.0 | -10.8 | -7.4 | -13.2 | -20.4 | · | |
| P / FCF | -3.3 | -6.2 | -5.4 | -3.8 | -11.3 | -27.1 | -21.1 | -10.7 | -7.3 | -12.7 | -19.2 | · | |
| EV / EBITDA | -2.1 | · | · | · | · | · | · | · | · | · | · | · | |
| EV / FCF | -2.5 | · | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 3.1 | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -39.9% | -17.3% | -23.2% | -39.0% | -11.7% | -4.0% | -5.7% | · | · | · | · | · |
Estado de resultados 15
| Métrica | Tendencia | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $71M | $87M | $67M | $60M | $49M | $74M | $59M | $31M | $715.0K | $482.0K | $469.0K | $238.0K | · | · | · | · | |
| Cost of Revenue | $42M | $28M | $38M | $57M | $43M | $23M | $32M | $31M | $7M | $-5M | $4M | $2M | · | · | · | · | |
| R&D Expense | $62M | $69M | $75M | $79M | $76M | $67M | $67M | $62M | $80M | $77M | $88M | $86M | $83M | $81M | $73M | $73M | |
| SG&A Expense | $39M | $36M | $35M | $38M | $44M | $42M | $39M | $40M | $31M | $29M | $27M | $22M | $28M | $26M | $28M | $26M | |
| Operating Expenses | $152M | $160M | $162M | $174M | $171M | $160M | $148M | $133M | $118M | $122M | $119M | $110M | $111M | $107M | $100M | $100M | |
| Operating Income | $-81M | $-73M | $-95M | $-114M | $-121M | $-87M | $-89M | $-102M | $-118M | $-121M | $-118M | $-110M | $-111M | $-107M | $-100M | $-100M | |
| Interest Income | $1M | $2M | $1M | $4M | $3M | $10M | $4M | $3M | $3M | $3M | $3M | $3M | $3M | $2M | $777.0K | $385.0K | |
| Pretax Income | $-80M | $-72M | $-94M | $-110M | $-118M | $-77M | $-85M | $-99M | $-114M | $-118M | $-115M | $-107M | $-107M | $-105M | $-100M | $-99M | |
| Income Tax | $-665.0K | $184.0K | $-2M | $2M | $-2M | $2M | $-2M | $-1M | $-1M | $-2M | $-1M | $-477.0K | $0 | · | · | · | |
| Net Income | $-79M | $-72M | $-91M | $-112M | $-116M | $-79M | $-84M | $-97M | $-113M | $-116M | $-114M | $-107M | $-107M | $-105M | $-100M | $-99M | |
| EPS (Basic) | $-0.19 | $-0.15 | $-0.25 | $-0.33 | $-0.36 | $-0.24 | $-0.28 | $-0.34 | $-0.42 | $-0.46 | $-0.46 | $-0.47 | $-0.50 | $-0.65 | $-0.63 | $-0.63 | |
| EPS (Diluted) | $-0.19 | · | · | $-0.33 | $-0.36 | $-0.24 | $-0.28 | $-0.34 | $-0.42 | $-0.46 | $-0.46 | $-0.47 | $-0.50 | $-0.65 | $-0.63 | $-0.63 | |
| Shares (Basic) | 418,511 | -664,071 | 364,037 | 334,511 | 322,868 | -564,429 | 303,269 | 284,817 | 266,220 | -213,929,167 | 245,817 | 224,481 | 213,694,000 | -472,044,741 | 157,817,000 | 157,274,000 | |
| Shares (Diluted) | 418,511 | · | · | 334,511 | 322,868 | -564,429 | 303,269 | 284,817 | 266,220 | -213,929,167 | 245,817 | 224,481 | 213,694,000 | -472,044,741 | 157,817,000 | 157,274,000 | |
| EBITDA | $-78M | · | $-95M | $-110M | $-118M | · | $-86M | $-99M | $-115M | · | $-115M | $-107M | $-108M | · | $-100M | $-100M |
Balance general 27
| Métrica | Tendencia | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $197M | $163M | $158M | $132M | $172M | $116M | $164M | $229M | $134M | $115M | $268M | $230M | $543M | $232M | $118M | $108M | |
| Short-term Investments | $117M | $134M | $143M | $169M | $188M | $208M | $233M | $184M | $222M | · | $94M | $21M | $83M | · | $242M | $316M | |
| Receivables | $82M | $82M | $67M | $60M | $71M | $69M | $56M | $32M | $234.0K | · | · | $33.0K | · | · | · | · | |
| Inventory | $58M | $52M | $52M | $50M | $66M | $52M | $39M | $28M | $18M | · | $9M | $10M | · | · | · | · | |
| Prepaid Expense | $13M | $12M | $10M | $12M | $16M | $12M | $7M | $10M | $11M | · | $12M | $14M | $11M | · | $10M | $7M | |
| Current Assets | $467M | $443M | $429M | $422M | $513M | $457M | $499M | $482M | $386M | · | $383M | $275M | $638M | · | $370M | $432M | |
| PP&E (Net) | $131M | $131M | $127M | $122M | $112M | $109M | $113M | $111M | $112M | · | $113M | $113M | $110M | · | $101M | $101M | |
| PP&E (Gross) | $184M | $180M | $172M | $165M | $150M | $145M | $149M | $145M | $143M | · | $138M | $135M | $129M | · | $115M | $113M | |
| Accum. Depreciation | $52M | $49M | $45M | $42M | $39M | $36M | $37M | $34M | $31M | · | $25M | $22M | $19M | · | $14M | $11M | |
| Intangibles | $269M | $279M | $285M | $296M | $285M | $282M | $307M | $295M | $294M | · | $224M | $236M | · | · | · | · | |
| Other Non-current Assets | $8M | $8M | $9M | $10M | $426.0K | $369.0K | $280.0K | $327.0K | $259.0K | · | $282.0K | $294.0K | $202.0K | · | $596.0K | $856.0K | |
| Total Assets | $926M | $913M | $905M | $907M | $967M | $910M | $991M | $964M | $870M | · | $852M | $757M | $825M | · | $546M | $611M | |
| Accounts Payable | $37M | $22M | $31M | $32M | $28M | $28M | $32M | $20M | $26M | · | $19M | $31M | $32M | · | $24M | $20M | |
| Accrued Liabilities | $88M | $111M | $87M | $89M | $85M | $82M | $75M | $62M | $46M | · | $61M | $47M | $43M | · | $48M | $38M | |
| Short-term Debt | $1M | $1M | $1M | $1M | $1M | · | · | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $129M | $138M | $126M | $129M | $123M | $122M | $118M | $94M | $83M | · | $91M | $89M | $87M | · | $79M | $64M | |
| Capital Leases | $44M | $44M | $45M | $45M | $44M | $44M | $66M | $69M | $72M | · | $68M | $69M | $70M | · | $72M | $73M | |
| Deferred Tax | $31M | $32M | $32M | $35M | $32M | $32M | $32M | $32M | $33M | · | $18M | $20M | · | · | · | · | |
| Total Liabilities | $204M | $215M | $203M | $209M | $199M | $200M | $218M | $196M | $190M | · | $178M | $179M | $158M | · | $152M | $138M | |
| Total Debt | $1M | · | $1M | $1M | $1M | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $18.0K | $17.0K | $16.0K | $14.0K | $14.0K | $13.0K | $13.0K | $12.0K | $12.0K | · | $11.0K | $9.0K | $9.0K | · | $7.0K | $7.0K | |
| Paid-in Capital | $3.56B | $3.46B | $3.39B | $3.29B | $3.26B | $3.10B | $3.06B | $2.99B | $2.81B | · | $2.58B | $2.36B | $2.34B | · | $1.86B | $1.84B | |
| Retained Earnings | $-2.85B | $-2.78B | $-2.70B | $-2.61B | $-2.50B | $-2.38B | $-2.31B | $-2.22B | $-2.13B | · | $-1.90B | $-1.78B | $-1.68B | · | $-1.46B | $-1.36B | |
| AOCI | $13M | $16M | $16M | $21M | $6M | $-1M | $16M | $526.0K | $116.0K | · | $-9M | $325.0K | $-126.0K | · | $-2M | $-3M | |
| Stockholders' Equity | $722M | $699M | $702M | $698M | $768M | $710M | $773M | $769M | $680M | $585M | $674M | $579M | $667M | $500M | $394M | $473M | |
| Liabilities + Equity | $926M | $913M | $905M | $907M | $967M | $910M | $991M | $964M | $870M | · | $852M | $757M | $825M | · | $546M | $611M | |
| Shares Outstanding | 438,106,537 | 411,938,061 | 385,461,728 | 341,919,364 | 333,934,387 | 305,252,194 | 304,620,470 | 297,305,999 | 279,756,339 | · | 255,833,679 | 224,688,434 | 224,358,979 | · | 157,840,581 | 157,800,581 |
Flujo de Efectivo 15
| Métrica | Tendencia | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $3M | $4M | $3M | $3M | $3M | $2M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $2M | $2M | |
| Stock-based Comp | $11M | $12M | $12M | $15M | $23M | $31M | $31M | $30M | $17M | $14M | $16M | $17M | $16M | $20M | $20M | $22M | |
| Deferred Tax | $-665.0K | $184.0K | $-2M | $2M | $-2M | $2M | $-2M | $-1M | $-1M | $-2M | $-1M | $-477.0K | $0 | · | $0 | · | |
| Amort. of Intangibles | $6M | $6M | $6M | $6M | $5M | $11M | $6M | $6M | $5M | $4M | $4M | $2M | $0 | · | $0 | $0 | |
| Restructuring | · | $0 | $5M | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | $-6M | · | · | · | $-11M | · | · | · | $-28M | · | · | · | $-11M | · | · | · | |
| Operating Cash Flow | $-72M | $-53M | $-79M | $-67M | $-104M | $-73M | $-59M | $-98M | $-122M | $-84M | $-84M | $-94M | $-100M | $-78M | $-64M | $-78M | |
| CapEx | $7M | $9M | $11M | $7M | $6M | $4M | $2M | $442.0K | $4M | $4M | $4M | $10M | $6M | $3M | $1M | $5M | |
| Investing Cash Flow | $11M | $775.0K | $17M | $14M | $16M | $24M | $-49M | $40M | $-112M | $-73M | $-79M | $-157M | $153M | $461.0K | $74M | $96M | |
| Debt Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | |
| Stock Issued | $99M | $56M | $89M | $13M | $149M | $0 | $48M | $152M | $198M | $1.0K | $203M | $0 | $260M | $190M | $0 | $0 | |
| Net Stock Activity | $99M | · | · | · | $149M | · | · | · | $198M | · | · | · | $260M | · | · | · | |
| Financing Cash Flow | $94M | $56M | $88M | $13M | $143M | $2M | $42M | $153M | $194M | $962.0K | $203M | $1M | $258M | $191M | $225.0K | $-2M | |
| Net Change in Cash | $33M | $5M | $26M | $-40M | $56M | $-48M | $-65M | $94M | $-41M | $-153M | $38M | $-253M | $312M | $113M | $10M | · | |
| Free Cash Flow | $-79M | · | · | · | $-110M | · | · | · | $-126M | · | · | · | $-105M | · | · | · |
Rentabilidad 7
| Métrica | Tendencia | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -113.5% | · | -140.7% | -189.8% | -245.8% | · | -152.1% | -327.6% | -16464.6% | · | -25236.9% | -46254.6% | · | · | · | · | |
| Net Margin | -110.7% | · | -135.3% | -186.2% | -235.5% | · | -142.7% | -312.2% | -15800.8% | · | -24255.9% | -44759.7% | · | · | · | · | |
| Pretax Margin | -111.6% | · | -138.8% | -182.9% | -239.2% | · | -145.3% | -316.8% | -15997.8% | · | -24520.9% | -44960.1% | · | · | · | · | |
| EBITDA Margin | -109.5% | · | -140.7% | -184.1% | -240.1% | · | -147.0% | -318.0% | -16048.1% | · | -24618.5% | -45036.1% | · | · | · | · | |
| ROA | -8.3% | · | -9.6% | -11.9% | -12.7% | · | -9.1% | -11.3% | -13.3% | · | -16.3% | -15.6% | -14.1% | · | -14.5% | -13.6% | |
| ROE | -10.6% | · | -12.4% | -15.2% | -16.1% | · | -11.5% | -14.4% | -16.8% | · | -21.3% | -20.3% | -17.6% | · | -18.2% | -16.3% | |
| ROIC | -11.1% | · | -13.2% | -16.6% | -15.5% | · | -11.3% | -13.1% | -17.1% | · | -17.4% | -18.9% | · | · | · | · |
Liquidez y Solvencia 3
| Métrica | Tendencia | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.6 | · | 3.4 | 3.3 | 4.2 | · | 4.2 | 5.2 | 4.6 | · | 4.2 | 3.1 | 7.3 | · | 4.7 | 6.7 | |
| Quick Ratio | 3.1 | · | 2.9 | 2.8 | 3.5 | · | 3.8 | 4.7 | 4.3 | · | 4.0 | 2.8 | 7.2 | · | 4.5 | 6.6 | |
| Debt / Equity | 0.0 | · | 0.0 | 0.0 | 0.0 | · | · | · | · | · | · | · | · | · | · | · |
Eficiencia 3
| Métrica | Tendencia | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.0 | 0.0 | · | 0.0 | 0.0 | · | · | · | · | |
| Inventory Turnover | 0.7 | · | 0.9 | 1.5 | 1.2 | · | 1.7 | 1.7 | 0.8 | · | 0.9 | 0.4 | · | · | · | · | |
| Receivables Turnover | 0.9 | · | 1.1 | 1.3 | 1.4 | · | 2.1 | 2.0 | 6.1 | · | · | 14.4 | · | · | · | · |
Valoración (TTM) 14
| Métrica | Tendencia | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $248M | · | $235M | $199M | $140M | · | $91M | $33M | · | · | · | · | $0 | · | $0 | $0 | |
| Net Income TTM | $-398M | · | $-403M | $-408M | $-410M | · | $-407M | $-430M | $-441M | · | $-427M | $-413M | $-398M | · | $-377M | $-358M | |
| Market Cap | $1.54B | · | $836M | $588M | $1.11B | · | $2.86B | $2.38B | $4.15B | · | $1.16B | $1.58B | $1.37B | · | $1.51B | $1.74B | |
| Enterprise Value | $1.23B | · | $537M | $288M | $753M | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | · | · | -1.7 | -1.3 | -2.4 | · | -6.3 | -4.7 | -8.0 | · | -2.2 | -3.2 | -2.6 | · | -4.0 | -4.8 | |
| P/S | 6.2 | · | 3.6 | 3.0 | 8.0 | · | 31.5 | 73.3 | · | · | · | · | · | · | · | · | |
| P/B | 2.1 | · | 1.2 | 0.8 | 1.4 | · | 3.7 | 3.1 | 6.1 | · | 1.7 | 2.7 | 2.1 | · | 3.8 | 3.7 | |
| P / Tangible Book | 3.4 | · | 2.0 | 1.5 | 2.3 | · | 6.1 | 5.0 | 10.7 | · | 2.6 | 4.6 | 2.1 | · | 3.8 | 3.7 | |
| P / Cash Flow | -21.3 | · | · | · | -10.7 | · | · | · | -33.9 | · | · | · | -13.7 | · | · | · | |
| P / FCF | -19.5 | · | · | · | -10.1 | · | · | · | -32.8 | · | · | · | -13.0 | · | · | · | |
| EV / EBITDA | -15.7 | · | -5.7 | -2.6 | -6.4 | · | · | · | · | · | · | · | · | · | · | · | |
| EV / FCF | -15.6 | · | · | · | -6.9 | · | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 4.9 | · | 2.3 | 1.4 | 5.4 | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | · | · | -60.4% | -76.2% | -42.0% | · | -16.0% | -21.1% | -12.5% | · | -45.3% | -31.7% | -38.3% | · | -24.9% | -20.7% |
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
Estado de resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ingresos | $264M | $164M | $1M | — | — |
| Margen Operativo % | -153.1% | -240.9% | -38735.0% | — | — |
| Beneficio neto | $-391M | $-372M | $-444M | $-396M | $-342M |
| EPS Diluido | $-1.09 | $-1.28 | $-1.89 | $-2.49 | $-2.23 |
Balance general
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Deuda / Patrimonio | 0.0 | — | — | — | — |
| Ratio corriente | 3.2 | 3.7 | 2.8 | 5.2 | 5.7 |
| Ratio Rápido | 2.7 | 3.2 | 2.5 | 5.2 | 5.7 |
Flujo de Efectivo
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flujo de caja libre | $-336M | $-364M | $-384M | $-313M | $-266M |
Últimas noticias Noticias recientes que mencionan a esta empresa
- Chardan Recorta Precio Objetivo de Iovance (IOVA) a $14, Mantiene Calificación de Compra
- Iovance Biotherapeutics Llamada de resultados del primer trimestre Puntos destacados
- El sentimiento de los analistas sigue siendo fuerte en Iovance Biotherapeutics (IOVA) en medio del lanzamiento en EE.UU. del medicamento para el melanoma, Amtagvi
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
📊
Elige las métricas que te importan — haz clic en el ➕ junto a cualquier fila en Fundamentales Completos arriba.
Tu selección se guarda y te sigue en todos los tickers.